Innoviva, Inc. <INVA.O>: Oppenheimer assumes coverage with outperform rating; price target $35
INVA•Related News
Oruka falls after reporting mid-stage data for psoriasis drug
ORKA•
Better disputes ex-CEO Vishal Garg claim of 46% shareholder support for consent push
BETR•
SoFi survey finds 59% of Americans rate enjoying life above homeownership as financial progress marker
SOFI•
Northrop Grumman <NOC.N>: Bernstein cuts target price to $620 from $653
NOC•
Paychex FY27 Q1 diluted EPS climbs 14% to $1.21; revenue rises 6% to $1.63 billion
PAYX•